



SDMA validation in human blood samples

To further explore SDMA's potential applications to human health, IDEXX in collaboration with Yale University, a world-leading human nephrology research organization, has validated the IDEXX SDMA[®] Test for accuracy in measuring SDMA in human blood samples. SDMA is the subject of more than 30 ongoing research collaborations.

IDEXX and Yale University— a collaboration in validating human blood samples

This novel immunoassay for measuring Symmetric Dimethylarginine (SDMA) with comparable performance to LC-MS/MS is now validated for use in humans and is better suited for high-throughput clinical laboratory testing. This assay will facilitate further research and widespread clinical adoption of this emerging biomarker for renal function. This underscores IDEXX's leadership in the renal market and shows that the IDEXX SDMA Test is becoming commonly appreciated as an essential element of the routine chemistry panel. Future collaborative research will continue to focus on the clinical utility of SDMA in human patients using the validated IDEXX SDMA Test.

A more efficient biomarker for kidney function

Symmetric dimethylarginine (SDMA) is a by-product of protein methylation and degradation that is primarily eliminated by the kidneys. It is freely filtered at the glomerulus, with no active secretion or reabsorption by the renal tubules. As a result, SDMA plasma concentrations are affected by changes in GFR and it is emerging as a kidney function biomarker that has outperformed serum creatinine in several studies.

Whether the kidney condition is chronic, acute, or a secondary consequence of other common diseases found in veterinary medicine, SDMA provides the unique opportunity to gain important insights.

Sources:

<https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2783876>
<https://www.idexx.com/en/about-idexx/news/idexx-launches-sdma-point-care-idexx-catalyst-sdma-test/>